An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Abiomed, Inc. (NASDAQ: ABMD), a frontrunner in heart, lung, and kidney support technologies, has announced that Michael R. Minogue, its Chairman, President, and CEO, will present at the William Blair 42nd Annual Growth Stock Conference. The presentation is scheduled for Monday, June 6, 2022, at 2:00 PM CT. Based in Danvers, Massachusetts, Abiomed specializes in medical devices that enhance blood flow and oxygenation, assisting patients in respiratory failure.
Positive
None.
Negative
None.
DANVERS, Mass.--(BUSINESS WIRE)--
Abiomed, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present (live) at the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022 at 2:00pm CT.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.